eXmoor Pharma Ltd raises US$35m
Bristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.
The financing of eXmoor Pharma Ltd. was led by new investor Kineticos Ventures and existing investor MVM Partners to help launching the companys GMP-compliant cell and gene therapy centre aimed to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors. with the financing eXmoor turns into a full-service CGT contract development and manufacturing organisation (CDMO).
According to Frank Lis, President and Chief Executive Officer of Kineticos Ventures, who joined eXmoors Board upon the financing round, the companys team has helped develop more than 50 clinical programs and designed 37 CGT facilities. The new Cell and Gene Therapy Centre, opening in Bristol in July 2023, will feature a mixture of manufacturing cleanrooms, Process and Analytical Development and QC laboratories, and associated support spaces suitable for all types of CGTs.
Angela Osborne, Chief Executive Officer of eXmoor Pharma Concepts Ltd added that the biggest bottleneck in CGT manufacturing isnt just capacity, but capability. Founded in 2004, eXmoor has specialized in the CGT sector since 2007 supporting clients to choose an appropriate CMC strategy.
